Dragonfly is positioned to establish itself as a leading biosimilar company whose products will meet the highest technical standards of comparability. The company has established its state-of-the-art drug development operations in Shanghai, China.

Dragonfly’s biologics platform is based on the following core technologies:

By integrating these technologies, Dragonfly “reverse engineers” biosimilar products that are comparable to the reference product. Dragonfly’s biosimilars are subjected to a variety of analytical techniques to characterize:

• Amino acid sequence
• Post-translational modifications including N and O linked glycan analysis
• Peptide mapping
• Di-sulfide bonds
• Charge and size heterogeneity
• Biological potency
• Binding activity

The results of these analyses ensure that the Dragonfly biosimilar product meets stringent specifications when compared to the structure and activity of the originator drug products.

Dragonfly’s pipeline of programs includes product candidates for major multi-billion dollar antibody products.